Floatz logo

Nexiguran Ziclumeran

Genetic Disease, Inborn

Intellia TherapeuticsPhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

9 Active assets in the Genetic Disease, Inborn cohort.

Asset / SponsorPhaseRating
DEXAMETHASONE
Intergroupe Francophone du Myelome
Phase 3BB
Aoc 1044
Avidity Biosciences, Inc.
Phase 3B
DEXAMETHASONE
Quince Therapeutics S.p.A.
Phase 3B
Zeleciment Rostudirsen
Dyne Therapeutics
Phase 3B
Thalidomide
National Institute of Blood and Marrow Transplant (NIBMT), Pakistan
Phase 2CCC

View all 16 →

Same molecule, other indications

Nexiguran Ziclumeran is also rated in:

neurodegeneration with brain iron accumulationDormant
B
Indicative ·
60 / 100
View asset →
inherited neurodegenerative disorderDormant
B
Indicative ·
60 / 100
View asset →
neuromuscular diseaseDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →